This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

AbbVie, Amgen accused of illegally delaying generic Humira

( March 20, 2019, 22:31 GMT | Official Statement) -- MLex Summary: Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund filed a proposed class action accusing AbbVie and Amgen of unlawfully restraining competition in the market for the drug Humira and its biosimilar competitors. The complaint claims AbbVie has created a “patent thicket” - securing over 100 patents designed solely to insulate Humira from competition - and entered into illegal agreements to delay biosimilar entry in the US.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections